Novel ThickNet features for the discrimination of amnestic MCI subtypes

Pradeep Reddy Raamana1, Wei Wen2, Nicole A Kochan2

  • 1School of Engineering Science, Simon Fraser University, Burnaby V5A 1S6, Canada.

Neuroimage. Clinical
|November 8, 2014
PubMed
Abstract

Insights

This study introduces ThickNet, a novel classifier for distinguishing subtypes of mild cognitive impairment (MCI). ThickNet shows promise in identifying individuals with multi-domain MCI (md-MCI) at higher risk for Alzheimer's disease progression.

Area of Science:

  • Neuroimaging
  • Machine Learning
  • Cognitive Neuroscience

Background:

  • Amnestic mild cognitive impairment (aMCI) is a precursor to Alzheimer's disease (AD).
  • aMCI has subtypes: single-domain (sd-aMCI) and multi-domain (md-aMCI).
  • md-aMCI carries a higher risk of progression to AD.

Purpose of the Study:

  • To develop and evaluate a novel classifier, ThickNet, for discriminating between aMCI subtypes and healthy controls.
  • To assess the potential of ThickNet for early detection of Alzheimer's disease by identifying individuals at risk.

Main Methods:

  • Utilized novel Thickness Network (ThickNet) features derived from cortical thickness co-variation graphs.
  • Employed multiple kernel learning to fuse ThickNet features for a composite classifier.
  • Applied the ThickNet classifier to baseline T1 MRI scans from the Sydney Memory and Ageing Study.

Main Results:

  • ThickNet achieved an AUC of 0.74 for discriminating md-aMCI from healthy controls (NC).
  • The classifier yielded AUCs of 0.67 for sd-aMCI/NC and 0.67 for sd-aMCI/md-aMCI discrimination.
  • Demonstrated improved performance over methods using only cortical thickness.

Conclusions:

  • The ThickNet classifier shows potential for discriminating md-aMCI from controls and sd-aMCI from md-aMCI.
  • This approach, using baseline MRI and novel cortical features, may enable earlier detection of AD.
  • ThickNet offers a promising tool for improved discrimination of aMCI subtypes.

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
4
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
737
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
6
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
933